Doximity, Inc.

NYSE: DOCS·San Francisco, California·

Price
$32.77
Base IV
$14.02

Valuation snapshot

Above bull case

At $32.77, the price is above even our bull case of $22.87.

Values per share, from an .

No growth
…
Loading earnings power
Base case
$14.02
43% of the price · range $7.25–$22.87
Price vs base case
134% above
$32.77 against $14.02
Base casevalued by DCF
Price vs base
Priceclose 11‑16

Whisker on the base case runs bear $7.25 to bull $22.87. Values per share.

Price against each value

Bear case
$7.25
Price 352% above
No growth
…
—
Base case
$14.02
Price 134% above
Researched bygemini-3.8-flash-medium
Valuation Nov 6, 2026 · Price as of Nov 16, 2026How we got here

What does Doximity do?

Doximity provides a professional network and software tools that help physicians manage clinical workflows, collaborate with colleagues, and allow pharmaceutical companies to reach medical professionals.

It brought in $661.6M of sales in the 12 months to Sep 2026.

Led by Jeffrey Tangney, Chief Executive Officer since 2010. Doximity, Inc. Definitive Proxy Statement (Form DEF 14A)

Industry
Technology
Based in
San Francisco, California
Trades on
NYSE as DOCS

Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 21¢ was left as profit after every cost, interest and tax. The biggest cost is sales, marketing and admin, 37¢ of every dollar.

  • Making what it sells13¢
  • Research and development23¢
  • Sales, marketing and admin37¢
  • Tax10¢
  • Left as profit21¢
  • Interest and other income came back in+4¢
Totals of the four quarters to Sep 2026, from the company's own filings.

Who pays Doximity, and for what?

Doximity operates an online professional network and clinical workflow platform used by over 85% of U.S. physicians. The platform is free for medical professionals, and Doximity makes money mainly by selling subscriptions to drugmakers, hospitals, and recruiters to reach doctors with medical content, job openings, and telehealth and AI tools.

Pharmaceutical manufacturers, hospitals and health systems, and medical recruiting firms pay for subscriptions and staffing services, with customers spending over $500,000 a year generating about 83% of revenue.

  • Marketing Solutions

    Subscriptions that let pharmaceutical companies and health systems share targeted medical articles, videos, and clinical updates with relevant doctors in their newsfeeds and daily workflow tools.

  • Hiring Solutions

    Subscriptions that let hospitals and recruiting firms post medical jobs and message candidates on the network, alongside full-service permanent and temporary physician staffing through Curative Talent.

  • Workflow Solutions

    Enterprise subscriptions for hospitals and health systems covering voice and video telehealth (Dialer), doctor on-call scheduling (AMiON), ambient AI note-taking (Scribe), and clinical AI reference (Ask).

We don't have each line's share of sales for this company yet.

FY2026 Form 10-K (Item 1 & Item 7)

How is the business doing?

Sales grew from $206.9M in 2021 to $644.9M in 2026, about 26% a year.

Running the business leaves about 26¢ of each sales dollar as operating profit, about the same as 26¢ in 2021.

Sales$644.9M
20212026
Operating margin33%
20212026
Each bar is one fiscal year (2021–2026), summed from four published quarters; the latest is highlighted.

What does management say it's aiming for?

Doximity aims to make doctors more productive so they can spend less time on paperwork and provide better care to patients.

“Our mission is to help every physician be more productive and provide better care for their patients.”

FY2026 Form 10-K (Item 1)

Who is responsible for the plan?

Roles checked November 14, 2026.

What management says it is working on now:

  • Expand the Clinical AI Suite and monetize workflow tools

    Doximity is investing in its AI assistant (Ask), ambient note-taker (Scribe), and telehealth tools, which over 140 health systems have approved, to deepen daily physician usage and grow enterprise sales.

    FY2026 Form 10-K (Item 1)
  • Increase spending from existing pharmaceutical and hospital clients

    Management focuses on selling additional marketing modules and expanding across more medication brands and hospital service lines within existing customers, which drove 75% of subscription revenue growth in fiscal 2026.

    FY2026 Form 10-K (Item 1 & Item 7)
  • Grow network membership across more healthcare professions

    Beyond U.S. physicians, Doximity is working to register more nurse practitioners and physician assistants, and sees room to expand to dentists, physical therapists, and psychologists.

    FY2026 Form 10-K (Item 1)
  • Attract new enterprise customers and develop patient-facing tools

    The company is expanding direct sales outreach to win new drugmakers and health systems while building patient doctor-finder and scheduling tools alongside U.S. News & World Report.

    FY2026 Form 10-K (Item 1)
  • Return capital through share repurchases and evaluate acquisitions

    Doximity selectively acquires complementary tools like Pathway Medical and authorized a new $500 million share repurchase program in February 2026 after completing its prior $500 million buyback.

    FY2026 Form 10-K (Item 1 & Item 7)
Full-Year Revenue, FY2027 (ending March 31, 2027)
$671 million to $681 million
Q1 FY2027 Earnings Release (Form 8-K)
Full-Year Adjusted EBITDA, FY2027 (ending March 31, 2027)
$309 million to $329 million
Q1 FY2027 Earnings Release (Form 8-K)
Q2 Revenue, Q2 FY2027 (ending September 30, 2026)
$170 million to $171 million
Q1 FY2027 Earnings Release (Form 8-K)
Q2 Adjusted EBITDA, Q2 FY2027 (ending September 30, 2026)
$80.5 million to $81.5 million
Q1 FY2027 Earnings Release (Form 8-K)
Goals in management's own numbers. A target is a promise, not a result.

What's changing right now?

Growth is slowing. In Q2 2027 it sold 4% more than a year earlier. The year before, quarters averaged 11%.

Its operating margin is narrower than a year ago: 25¢ per sales dollar, against 38¢.

The share price is about where it was in Nov 2026, near $32.77.

Bull $22.87Base $14.02Bear $7.25Nov 3Nov 16 · $32.77
Daily closing prices we have recorded, set against our bear-to-bull range. Our price records start November 3, 2026.

Recently

Coming up

  • November 5, 2026

    Q2 Fiscal 2027 Earnings Release and Guidance Update

    Doximity will report fiscal second-quarter results and hold an investor conference call after market close, providing an update on pharmaceutical marketing demand, AI workflow adoption, and full-year fiscal 2027 guidance.

    Doximity Investor Relations Announcements
  • Throughout Fiscal 2027 (ending March 31, 2027)

    Enterprise Rollout and Monetization of Clinical AI Suite

    Continued commercial adoption of Doximity Ask, Scribe, and Dialer Enterprise across U.S. health systems following governance approvals at over 140 health systems.

    FY2026 Form 10-K (Item 1)

Our own estimate moved too: the base case went from $14.11 to $14.02 a share between our last two valuations.

What could go wrong?

No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.

  1. Customer concentration and short-term pharmaceutical contracts

    One customer accounted for at least 10% of fiscal 2026 revenue, and 125 large customers generated 83% of revenue. Drugmakers typically do not sign long-term contracts, so losing or renegotiating a major account could sharply slow growth.

    From the company's own filingsWould hit how fast sales growFY2026 Form 10-K (Item 1A & Item 7)

  2. Slowing revenue growth and heavy AI and R&D spending

    Annual revenue growth slowed from 20% in fiscal 2025 to 13% in fiscal 2026 as the business matured. At the same time, heavy investments in AI computing, engineering, and stock-based compensation could weigh on profit margins.

    From the company's own filingsWould hit how much of each sale it keepsFY2026 Form 10-K (Item 1A & Item 7)

  3. Intensifying competition across medical media, telehealth, and AI

    Doximity competes with medical sites like Medscape, telehealth providers like Teladoc and Zoom, and emerging clinical AI tools like OpenEvidence, Abridge, OpenAI, and Anthropic, which could pressure pricing or member engagement.

    From the company's own filingsWould hit how fast sales growFY2026 Form 10-K (Item 1 & Item 1A)

  4. Strict healthcare privacy, anti-kickback, and emerging AI regulations

    Handling patient and doctor data subjects Doximity to HIPAA, state privacy laws, and healthcare fraud rules, while evolving laws on AI in medicine could restrict how doctors use its tools or expose the company to penalties.

    From the company's own filingsWould hit how much of each sale it keepsFY2026 Form 10-K (Item 1 & Item 1A)

  5. Reliance on physician trust, active usage, and accurate profiles

    The value of Doximity's marketing and recruiting tools depends on doctors actively using the app and keeping their profiles current. Any loss of physician trust or dip in engagement would make the platform less attractive to paying clients.

    From the company's own filingsWould hit how fast sales growFY2026 Form 10-K (Item 1A)

  6. Macroeconomic and policy uncertainty affecting pharma marketing budgets

    Economic slowdowns, inflation, tariffs, or healthcare policy shifts can cause pharmaceutical companies and hospitals to delay decisions or cut discretionary digital marketing and recruiting budgets.

    From the company's own filingsWould hit how fast sales growFY2026 Form 10-K (Item 1A & Item 7)

  7. Year-over-year revenue growth in FY2027 Q2 was 3.57%, down from 23.16% in the prior-year period.

    From our researchWould hit how fast sales growDoximity Q2 FY2027 Report

  8. Occasional technology acquisitions or expanded third-party AI licensing commitments could increase capital outlays.

    From our researchWould hit how much it has to reinvestDoximity Form 10-K M&A Disclosures

Is it a good business?

From 2021 to 2026 it earned between 12% and 75% on its shareholders' equity, a median of 19%.

Over 6 years its operating margin ranged from 26¢ to 40¢ per sales dollar, a median of 33¢. Gross margin ran from 85¢ to 90¢.

derived computed from the filingsassumption cost of capital from the latest valuation
Return on equity21%
20212026
Return on invested capital is operating profit after tax (at the median effective rate, 15%) over debt plus equity less cash at each fiscal year end. Return on equity is net income over equity. Both are computed from published quarters.

It bought back shares: the count fell 6.4% in a year, so each remaining share owns a slightly bigger slice.

What might it be worth?

Net debt is excluded: The reported balance sheet does not yet establish a complete debt figure. The per-share value may change when resolved. No earlier published debt figure is available.

The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .

Today a share costs $32.77. Our put its value between $7.25 and $22.87, with $14.02 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .

Bear case, $7.25

This scenario envisions that sales growth slows down to low single digits following recent sluggish quarterly results, while rising operational expenses keep company profits below past peaks.

Base case, $14.02

This scenario expects revenue growth to stabilize in the mid-single digits as pharmaceutical marketing budgets steady and hospital client renewals hold firm, allowing profits to recover toward multi-year historical averages.

Bull case, $22.87

This scenario envisions a strong rebound in demand as healthcare clients accelerate their adoption of new digital tools and artificial intelligence software, driving revenue growth back into double digits and expanding profitability toward past peaks.

Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.

Why the gap?

The price expects far more than we do.Price above value: 134%

For Doximity to be worth today's $32.77, sales would need to grow about 28.9% a year. We assume 7.0%. Over the last 5 years, sales grew 19.0% a year.

−10%0%+10%+20%+30%+40%We assume 7.0%Past 5 yrs 19.0%Price needs 28.9%

Or, if sales grow 7.0% as we assume, the price works with a profit margin of 74.8% (we assume 32.0%).

Keep in mind: investors are likely paying for things this model leaves out, such as new businesses or many more years of fast growth.

Do you think sales can grow 28.9% a year?

Try your own numbers

We're moderately sure of this range: it scores 57 out of 100 on our checks. The weakest point is terminal-value dependency.

Test the assumptions

Our base value of $14.02 rests on three assumptions. Change any of them to see how the value per share responds.

  • Revenue growth, 5-year average7.0%
  • Operating margin32.0%
  • Long-term growth rate2.8%

This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.

Base estimate

$14.02 -57.2%

Build